Dopamine D2-like receptor signaling suppresses human osteoclastogenesis

Bone

Volumn 56, Issue 1, 2013, Pages 1-8

  Hanami, Kentaro ^a   Nakano, Kazuhisa ^a   Saito, Kazuyoshi ^a   Okada, Yosuke ^a   Yamaoka, Kunihiro ^a   Kubo, Satoshi ^a   Kondo, Masahiro ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Bone resorption; Dopamine receptor; Osteoclast

Indexed keywords

CATHEPSIN K; CYCLIC AMP; DOPAMINE 2 RECEPTOR; MESSENGER RNA; PROTEIN C FOS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE METABOLISM; CATHEPSIN K GENE; CELL CULTURE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 84878381743     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2013.04.019     Document Type: Article

References (46)

1. Xing L., Schwarz E.M., Boyce B.F. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev 2005, 208:19-29.
2. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7:292-304.
3. Elefteriou F., Ahn J.D., Takeda S., Starbuck M., Yang X., Liu X., et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005, 434:514-520.
4. Fonseca T.L., Jorgetti V., Costa C.C., Capelo L.P., Covarrubias A.E., Moulatlet A.C., et al. Double disruption of α2A- and α2C -adrenoceptors results in sympathetic hyperactivity and high-bone-mass phenotype. J Bone Miner Res 2011, 26:591-603.
5. 2-adrenergic agonists on bone-resorbing activity in human osteoclast-like cells. Biochim Biophys Acta Mol Basis Dis 2003, 1640:137-142.
6. Missale C., Nash S.R., Robinson S.W., Jaber M., Caron M.G. Dopamine receptors: from structure to function. Physiol Rev 1998, 78:189-225.
7. Weihe E., Nohr D., Michel S., Muller S., Zentel H.J., Fink T., et al. Molecular anatomy of the neuro-immune connection. Int J Neurosci 1991, 59:1-23.
8. Bergquist J., Tarkowski A., Ekman R., Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci 1994, 91:12912-12916.
9. Cosentino M., Fietta A.M., Ferrari M., Rasini E., Bombelli R., Carcano E., et al. Human CD4+ CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 2007, 109:632-642.
10. Besser M.J., Ganor Y., Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFα or both. J Neuroimmunol 2005, 169:161-171.
11. Saha B., Mondal A.C., Majumder J., Basu S., Dasgupta P.S. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 2001, 9:23-33.
12. Watanabe Y., Nakayama T., Nagakubo D., Hieshima K., Jin Z., Katou F., et al. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J Immunol 2006, 176:848-856.
13. Nakano K., Higashi T., Hashimoto K., Takagi R., Tanaka Y., Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 2008, 373:286-291.
14. Nakashioya H., Nakano K., Watanabe N., Miyasaka N., Matsushita S., Kohsaka H. Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice. Mod Rheumatol 2011, 21:260-266.
15. Gaskill P.J., Carvallo L., Eugenin E.A., Berman J.W. Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. J Neuroinflammation 2012, 9:203.
16. Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci 2007, 1116:227-237.
17. Grigoriadis A., Wang Z., Cecchini M., Hofstetter W., Felix R., Fleisch H., et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266:443-448.
18. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z.Q., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004, 279:26475-26480.
19. Miyauchi A., Kuroki Y., Fukase M., Fujita T., Chihara K., Shiozawa S. Persistent expression of proto-oncogene c-fos stimulates osteoclast differentiation. Biochem Biophys Res Commun 1994, 205:1547-1555.
20. Gilman A.G. G proteins: transducers of receptor-generated signals. Annu Rev Biochem 1987, 56:615-649.
21. Olianas M.C., Onali P. Pertussis toxin attenuates D2 inhibition and enhances D1 stimulation of adenylate cyclase by dopamine in rat striatum. J Neurochem 1987, 48:1443-1447.
22. Abu-Amer Y., Ross F.P., Edwards J., Teitelbaum S.L. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997, 100:1557-1565.
23. Rastogi R.B., Singhal R.L. Evidence for the role of adrenocortical hormones in the regulation of noradrenaline and dopamine metabolism in certain brain areas. Br J Pharmacol 1978, 62:131-136.
24. Samii A., Nutt J.G., Ransom B.R. Parkinson's disease. Lancet 2004, 363:1783-1793.
25. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991, 148:1474-1486.
26. Brooks D.J. Dopamine agonists: their role in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 2000, 68:685-689.
27. Seifert R., Wenzel-Seifert K. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:381-416.
28. Al-Fulaij M.A., Ren Y., Beinborn M., Kopin A.S. Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants. J Mol Neurosci 2008, 34:211-223.
29. Yamada Y., Ando F., Niino N., Shimokata H. Association of a polymorphism of the dopamine receptor D4 gene with bone mineral density in Japanese men. J Hum Genet 2003, 48:629-633.
30. Kartaginer J., Ataya K., Mercado A., Abbasi A. Osteoporosis associated with neuroleptic treatment. A case report. J Reprod Med 1990, 35:198-202.
31. Meaney A.M., O'Keane V. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication. J Psychopharmacol 2003, 17:455-458.
32. Cronin H., Casey M.C., Inderhaugh J., Bernard Walsh J. Osteoporosis in patients with Parkinson's disease. J Am Geriatr Soc 2006, 54:1797-1798.
33. Ross F.P., Teitelbaum S.L. αvβ3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 2005, 208:88-105.
34. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
35. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004, 279:45969-45979.
36. Ljusberg J., Wang Y., Lang P., Norgard M., Dodds R., Hultenby K., et al. Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 2005, 280:28370-28381.
37. Di Bussolo V., Romano M.R., Favero L., Pineschi M., Crotti P. Stereoselective uncatalyzed synthesis of 2,3-unsaturated-4-n-substituted-beta-O-glycosides by means of a new d-galactal-derived N-(mesyl)-aziridine. J Org Chem 2006, 71:1696-1699.
38. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3:889-901.
39. Cho D.I., Quan W., Oak M.H., Choi H.J., Lee K.Y., Kim K.M. Functional interaction between dopamine receptor subtypes for the regulation of c-fos expression. Biochem Biophys Res Commun 2007, 357:1113-1118.
40. Fitzgerald J., Hughes-Fulford M. Mechanically induced c-fos expression is mediated by cAMP in MC3T3-E1 osteoblasts. FASEB J 1999, 13:553-557.
41. Koga K., Takaesu G., Yoshida R., Nakaya M., Kobayashi T., Kinjyo I., et al. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 2009, 30:372-383.
42. Fisch T.M., Prywes R., Simon M.C., Roeder R.G. Multiple sequence elements in the c-fos promoter mediate induction by cAMP. Genes Dev 1989, 3:198-211.
43. Robertson G.S., Fibiger H.C. Neuroleptics increase C-FOS expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 1992, 46:315-328.
44. Take I., Kobayashi Y., Yamamoto Y., Tsuboi H., Ochi T., Uematsu S., et al. Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 2005, 146:5204-5214.
45. Aitken S.J., Landao-Bassonga E., Ralston S.H., Idris A.I. Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms. Arch Biochem Biophys 2009, 482:96-103.
46. Biosse-Duplan M., Baroukh B., Dy M., de Vernejoul M.C., Saffar J.L. Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 2009, 174:1426-1434.